Form 4: Stoke Therapeutics CFO Granted Stock Options

Thomas Leggett, CFO of Stoke Therapeutics, was granted stock options for 396,200 shares on May 15, 2024.

Summary

• Thomas Leggett, the Chief Financial Officer of Stoke Therapeutics, Inc., was granted stock options on May 15, 2024.
• The options grant covers 396,200 shares of Stoke Therapeutics common stock.
• The exercise price of the stock options is $14.13 per share.
• The options vest as to 1/4 of the total award on May 7, 2025, and then 1/48 monthly thereafter, contingent upon continued service to the Issuer.

Sentiment

Score: 7

Explanation: The document is a routine disclosure of stock option grants, which is generally viewed as a neutral to slightly positive event as it incentivizes management.

Positives

• The granting of stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for CFOs in publicly traded biotechnology companies.
• The size of the grant and the vesting schedule are typical for executives at companies of Stoke Therapeutics' size and stage of development.
• Comparable companies such as Wave Life Sciences and Sarepta Therapeutics also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see the grant as a sign of the company's commitment to its leadership team.

Key Dates